Safety and effectiveness of pregabalin controlled-release in Korean patients with peripheral neuropathic pain: A post-marketing surveillance data.

ABSTRACT: Chronic pain, including neuropathic pain (NP), significantly affects quality of life in 7% to 10% of the general population. The prevalence of NP is rising owing to factors such as aging, obesity, and enhanced cancer survival rates. Effective management of NP is essential to improve patient outcomes. This study aimed to assess the safety and effectiveness of controlled-release (CR) pregabalin in Korean patients with peripheral NP . An open-label, non-comparative, multicenter study was conducted with 623 participants across 18 institutions. The patients received pregabalin CR as part of their routine treatment. Safety and efficacy data were collected over 12 weeks. Pain severity was assessed using the 11-point numeric rating scale (0 = no pain, 10 = worst imaginable pain), and sleep interfe

SUBMITTER: Oh SI 

PROVIDER: S-EPMC12459585 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature